Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 07, 2023 07:00 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Randi Isaacs, M.D., Chief Medical Officer of...
Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting
November 10, 2022 09:00 ET
|
Werewolf Therapeutics, Inc.
- mWTX-330 is designed as a systemically delivered, conditionally activated IL-12 therapy and is a member of a novel class of INDUKINE™ therapeutics - - Preclinical data supports the development of...
Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022 07:00 ET
|
Werewolf Therapeutics, Inc.
Dosed first patient in Phase 1/1b study evaluating WTX-124 as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) in advanced solid tumors; initial data anticipated in the fourth quarter...
Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences
November 07, 2022 16:05 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 07:00 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors
September 01, 2022 07:00 ET
|
Werewolf Therapeutics, Inc.
- First clinical candidate of a new class of systemically delivered conditionally activated INDUKINE™ therapeutics developed by Werewolf - WTX-124 is designed to target delivery of a highly potent,...
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
August 11, 2022 07:00 ET
|
Werewolf Therapeutics, Inc.
- FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for advanced solid tumors - - Submission of IND application for WTX-330 planned in 2H22 - - Q2 cash and cash...
Werewolf Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 03, 2022 07:00 ET
|
Werewolf Therapeutics, Inc.
WATERTOWN, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
June 06, 2022 16:51 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
May 10, 2022 07:00 ET
|
Werewolf Therapeutics, Inc.
- Entered exclusive global license and collaboration agreement with Jazz Pharmaceuticals to develop and commercialize WTX-613; received $15.0M upfront payment and eligibility for up to $1.26B in...